Alembic Pharmaceuticals receives USFDA approval for generic Dabigatran Etexilate capsules 75 mg & 150 mg, used for stroke and blood clot prevention in adults with atrial fibrillation. The company also received tentative approval for the 110 mg dosage.
New Delhi, Jun 18 (PTI) Alembic Pharmaceuticals Ltd on Tuesday said it has received final approval from the US health regulator for its generic Dabigatran Etexilate capsules 75 mg and 150 mg used to reduce risk of stroke and blood clots in adults with a certain medical condition.
The US Food & Drug Administration (USFDA) has also granted tentative approval for the Abbreviated New Drug Application (ANDA) for Dabigatran Etexilate capsules 110 mg, Alembic Pharmaceuticals, said in a statement.
The approved ANDA is therapeutically equivalent to the Reference Listed Drug product (RLD), Pradaxa Capsules, 75 mg, 110 mg, and 150 mg of Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer), it added.
The Dabigatran Etexilate capsules are indicated for the reduction of risk of stroke and systemic embolism in adults who have a medical condition called atrial fibrillation that is not caused by a heart valve problem.
It is also used in the treatment and reduction of the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients.
Alembic Pharma said Dabigatran Etexilate capsules 75 mg and 150 mg have an estimated market size of USD 179 million for 12 months ended March 2024 citing IQVIA data.
On the other hand, Dabigatran Etexilate Capsules 110 mg have an estimated market size of USD 5 million for 12 months ended March 2024, it added.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback